A Study to Evaluate SAGE-217 in Subjects With Severe Postpartum Depression
Status:
Completed
Trial end date:
2018-12-11
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of
the efficacy, safety and pharmacokinetics of SAGE-217 in approximately 140 adult female
subjects diagnosed with severe postpartum depression.